Blinatumomab

Cytokine Release Syndrome and Neurological Toxicities

• Cytokine Release Syndrome (CRS), which may be life-threatening or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended.[See Dosage and Administration (2.3), Warnings and Precautions (5.1)].
• Neurological toxicities, which may be severe, life-threatening, or fatal, occurred in patients receiving BLINCYTO. Interrupt or discontinue BLINCYTO as recommended. [See Dosage and Administration (2.3), Warnings and Precautions (5.2)

Approved Risk Evaluation and Mitigation Strategies (REMS)

Blincyto (blinatumomab) Injection

Patient Counseling Information

• BLINCYTO

Medication Guides

Patient Medication Guide

Package Inserts

Blinatumomab